Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care

Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall... INTRODUCTIONThe introduction of several new agents, such as proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), and most recently monoclonal antibodies (mAbs) as first‐line treatment in patients with multiple myeloma (MM) has contributed to a better overall survival (OS).1–3 Nevertheless, the conditioning regime with high‐dose melphalan (Mel, 200 mg/m2) followed by autologous stem cell transplantation (ASCT) is the established standard treatment for MM patients younger than 65 years of age and can improve both progression‐free survival (PFS) and OS radically, at least in some subgroups.4 However, the role of ASCT in the treatment of elderly patients is debatable, especially since the introduction of PI, IMiDs, and mABs as first‐line treatments.In MM, Mel is used almost exclusively as conditioning prior to ASCT. Typically, Mel is administered at a fixed dose of 200 mg/m2 (Mel200) except for patients with renal impairment for whom a dose reduction (140 mg/m2) is recommended. The toxicity of Mel in patients older than 65 years might pose a hurdle and is mostly attributed to the anticipated reduction in organ function as well as altered drug metabolism and excretion. Badros et al.5 described a small cohort of elderly patients who received Mel at a dose of either 200 mg/m2 or 140 mg/m2 prior to ASCT. The http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Haematology Wiley

Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care

Loading next page...
 
/lp/wiley/conditioning-with-melphalan-200-mg-m2-and-subsequent-asct-improves-t0M29JJSwx

References (45)

Publisher
Wiley
Copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
ISSN
0902-4441
eISSN
1600-0609
DOI
10.1111/ejh.13861
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONThe introduction of several new agents, such as proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), and most recently monoclonal antibodies (mAbs) as first‐line treatment in patients with multiple myeloma (MM) has contributed to a better overall survival (OS).1–3 Nevertheless, the conditioning regime with high‐dose melphalan (Mel, 200 mg/m2) followed by autologous stem cell transplantation (ASCT) is the established standard treatment for MM patients younger than 65 years of age and can improve both progression‐free survival (PFS) and OS radically, at least in some subgroups.4 However, the role of ASCT in the treatment of elderly patients is debatable, especially since the introduction of PI, IMiDs, and mABs as first‐line treatments.In MM, Mel is used almost exclusively as conditioning prior to ASCT. Typically, Mel is administered at a fixed dose of 200 mg/m2 (Mel200) except for patients with renal impairment for whom a dose reduction (140 mg/m2) is recommended. The toxicity of Mel in patients older than 65 years might pose a hurdle and is mostly attributed to the anticipated reduction in organ function as well as altered drug metabolism and excretion. Badros et al.5 described a small cohort of elderly patients who received Mel at a dose of either 200 mg/m2 or 140 mg/m2 prior to ASCT. The

Journal

European Journal of HaematologyWiley

Published: Dec 1, 2022

Keywords: aged; multiple myeloma; progression‐free survival; stem cell transplantation

There are no references for this article.